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Abstract
Background—Clinical trial registries are in widespread use to promote transparency around
trials and their results.
Objective—To describe characteristics of drug trials listed in ClinicalTrials.gov and examine
whether the funding source of these trials is associated with favorable published outcomes.
Design—An observational study of safety and efficacy trials for anticholesteremics,
antidepressants, antipsychotics, proton-pump inhibitors, and vasodilators conducted between 2000
and 2006.
Setting—ClinicalTrials.gov, a Web-based registry of clinical trials launched in 1999.
Measurements—Publications resulting from the trials for the 5 drug categories of interest were
identified, and data were abstracted on the trial record and publication, including timing of
registration, elements of the study design, funding source, publication date, and study outcomes.
Assessments were based on the primary funding categories of industry, government agencies, and
nonprofit or nonfederal organizations.
Results—Among 546 drug trials, 346 (63%) were primarily funded by industry, 74 (14%) by
government sources, and 126 (23%) by nonprofit or nonfederal organizations. Trials funded by
industry were more likely to be phase 3 or 4 trials (88.7%; P < 0.001 across groups), to use an
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active comparator in controlled trials (36.8%; P = 0.010 across groups), to be multicenter (89.0%;
P < 0.001 across groups), and to enroll more participants (median sample size, 306 participants; P
< 0.001 across groups). Overall, 362 (66.3%) trials had published results. Industry-funded trials
reported positive outcomes in 85.4% of publications, compared with 50.0% for government-
funded trials and 71.9% for nonprofit or nonfederal organization–funded trials (P < 0.001). Trials
funded by nonprofit or nonfederal sources with industry contributions were also more likely to
report positive outcomes than those without industry funding (85.0% vs. 61.2%; P = 0.013). Rates
of trial publication within 24 months of study completion ranged from 32.4% among industry-
funded trials to 56.2% among nonprofit or nonfederal organization–funded trials without industry
contributions (P = 0.005 across groups).
Limitations—The publication status of a trial could not always be confirmed, which could result
in misclassification. Additional information on study protocols and comprehensive trial results
were not available to further explore underlying factors for the association between funding source
and outcome reporting.
Conclusion—In this sample of registered drug trials, those funded by industry were less likely to
be published within 2 years of study completion and were more likely to report positive outcomes
than were trials funded by other sources.
Primary Funding Source—National Library of Medicine and National Institute of Child
Health and Human Development, National Institutes of Health.
ClinicalTrials.gov, a Web-based registry of clinical trials, was established in 1999 in
response to increasing concerns about the lack of transparency in the conduct of clinical
trials (1–4). The registry is a publicly available database of clinical trials and includes details
on the types of interventions applied, primary outcomes measured, basic results of the trials,
and organizations that funded the trials. Tracking the existence of clinical trials and a priori
primary outcome measures provides the potential to monitor the selective publication of
trials and trial results (5, 6).
Biased publication and reporting of results compromises the integrity of the medical
literature by providing an incomplete account of the evidence (2, 7, 8). Several studies have
highlighted widespread publication bias using documents submitted to drug licensing
agencies, federal funding agencies, and scientific review boards (9 –13). As many as one
half of trials supporting drugs that are approved by the U.S. Food and Drug Administration
(FDA) remain unpublished 5 years after drug approval, and examination of unpublished
results reveals striking discrepancies between existing trial results and results available in
the published literature (10, 13).
The use of such registries as ClinicalTrials.gov has been embraced by the International
Committee of Medical Journal Editors (ICMJE), and beginning in 2005, the ICMJE has
required trial registration before participant enrollment as a prerequisite for publication in
any of its member journals (14). In addition, the FDA Amendments Act of 2007 expanded
the scope of ClinicalTrials.gov to augment comprehensive trial registration and ensure
timely dissemination of trial results (15–17). However, little attention has been paid to
another key element that may affect the presentation of clinical evidence and that is tracked
in ClinicalTrials.gov: the funding source for clinical trials. We sought to describe
characteristics of trials registered in ClinicalTrials.gov for selected groups of drugs and to
examine whether the funding source of these trials is associated with published outcomes
favorable to the drug studied.
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Methods
Selection of Clinical Drug Trials
We identified all clinical trials registered in Clinical-Trials.gov as of 31 August 2009 that
studied anticholesteremics, antidepressants, antipsychotics, proton-pump inhibitors, and
vasodilators, including trials studying these drugs for FDA-approved and non–FDA-
approved indications (Figure 1). We chose these drug classes because they represent well-
defined groups of medications used to treat a broad spectrum of medical conditions. We
identified the specific medications within these drug categories by using the classification in
Lexi-Comp ONLINE (18), which classifies medications on the basis of their primary
mechanism of action. We identified trials studying these drugs and selected those that
started after 1 January 2000 and were completed by 31 December 2006. This approach
allowed at least 3 years between trial completion and our literature search for publication of
results. Trials that did not list a start date were excluded, and trials that did not list a
completion date were included only if the trial status was updated to “complete” by the
investigators before 31 December 2006. Finally, we included only safety or efficacy trials on
the basis of the study description provided in the record. We defined efficacy trials as those
studying the ability of a drug to produce a desired result and safety trials as those examining
adverse effects associated with therapy under conditions of proposed use (19, 20).
Data From ClinicalTrials.gov
Data on characteristics of the trials and their registration were extracted from the
ClinicalTrials.gov entry, including registration date, start date, completion date, condition
treated, funding source, trial phase, primary outcome, anticipated enrollment number, age
group of participants, and elements of the study design. Study completion date is defined by
ClinicalTrials.gov as the date when participants are no longer being examined or treated
(that is, the last patient’s final visit has occurred) (19). Each record was classified as
including study results in the form of links to PubMed abstracts, links to unpublished result
reports, or actual study results. All data were extracted independently by 2 authors, and
disagreements were resolved by consensus.
The primary sponsor funding the study is classified in the registry as “NIH” (National
Institutes of Health), “U.S. federal,” “other government,” “network,” “industry,”
“individual,” and “other” (which includes universities, hospitals, foundations, and other
nonprofit organizations). We categorized this variable into government (NIH, U.S. federal,
and other government), industry, and nonprofit or nonfederal organizations (network,
individual, and other). Secondary funding sources were categorized in the same manner. The
registry categorizes age at which participants were eligible for enrollment as “child” (age
≤17 years), “adult” (age 18 to 65 years), “senior” (age ≥66 years), and combinations of these
groups. We recoded the age group variable as children only, children and adults or seniors,
and adults and/or seniors. Condition under study was classified as an FDA-approved or a
non–FDA-approved indication on the basis of approval information provided on the drug
label at the time of trial initiation (21).
Identification of Associated Trial Publications
We systematically searched 4 electronic databases for publications corresponding to the
ClinicalTrials.gov trials. First, we searched PubMed by using names of principal
investigators listed in the record and keywords for drug names, condition studied, design
characteristics, study location, and outcome measures. We searched for publications in any
language. If more than 1 publication was identified, we chose the publication that most
closely fit the study description in the record. When a publication was not identified, we
searched the Cochrane Library, EMBASE, and CINAHL databases by using a similar search
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strategy. We also searched an online result registry, ClinicalStudyResults.org, and result
reports available through company Web pages for references to publications (22–24). For
trials that remained unmatched, we attempted to contact the investigator or pharmaceutical
company listed in the record with a maximum of 2 e-mails to inquire about publication
status. All searches were updated and finalized as of 15 March 2010.
For each publication, we recorded the date of publication and the actual number of
participants enrolled in the study. We examined the primary outcome and identified
discrepancies with the primary outcome listed in the ClinicalTrials.gov record (5). We also
examined results for the primary outcome and determined whether findings were favorable
or not favorable to the test drug. Results were considered favorable if they were statistically
significant (based on P values or CIs) and supported the efficacy or safety of the test drug or
not favorable if they were not statistically significant for the efficacy or safety of the test
drug (25). For noninferiority trials, if the test drug was equal to the comparison drug, the
results were also classified as favorable. Publications that did not describe results pertaining
to the safety or efficacy of the test drug (for example, early predictors of treatment response
or effects of different dosing regimens) were classified as “neither.” Two authors
independently did the literature search and data extraction, and disagreements were resolved
by consensus. Intercoder agreement for assigning trial outcomes was excellent (κ = 0.92
[95% CI, 0.88 to 0.97]).
Statistical Analysis
We report the frequency of characteristics of the drug trials by primary funding source. We
used chi-square tests to measure the association between funding source and trial
characteristics and to compare characteristics before and after the ICMJE policy
implementation. We used Cochran–Mantel–Haenszel tests to control for funding source
when examining the effect of the ICMJE policy on trial registration and the effect of trial
phase on reported outcomes. We examined changes in the rates of publication within 24
months of study completion by using a linear trend test for the 5 years between 2002 and
2006 (no trials were completed before 2002). We did a post hoc multivariate logistic
regression analysis to assess the association between funding source and trial outcome,
while controlling for other trial characteristics (drug class, approval status of indication,
study phase, multicenter status, anticipated sample size, age of study population, comparator
type, and length of study). We categorized funding source as industry, government, and
nonprofit or nonfederal, except when we examined publication and results reporting
characteristics, in which case trials with nonprofit or nonfederal funding were further
categorized on the basis of the inclusion of industry funding. All data were analyzed with
SAS software, version 9.1 (SAS Institute, Cary, North Carolina).
Role of the Funding Source
This research was funded by the National Library of Medicine and the National Institute of
Child Health and Human Development, NIH. The funding sources had no role in the design
of the study; collection, analysis, and interpretation of the data; preparation or review of the
manuscript; or the decision to submit the manuscript for publication.
Results
We included 546 drug trials in the analysis, of which 346 (63%) were primarily funded by
industry, 74 (14%) by government sources, and 126 (23%) by nonprofit or nonfederal
organizations. Three (4%) trials funded by government sources and 61 (48%) trials funded
by nonprofit or nonfederal sources received contributions from industry. For each of the
drug classes, industry was the most common primary funding source, accounting for 39% to
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89% of trials in each class (Figure 2). Of note, among the 346 industry-funded trials, 345
studied a drug developed or marketed by the company funding the trial.
Study Characteristics
Study characteristics of drug trials varied on the basis of the primary funding source (Table
1). Trials funded by industry were more likely to be phase 3 or 4 trials (88.7%; P < 0.001
across groups), to use an active comparator in controlled trials (36.8%; P = 0.010 across
groups), to be multicenter (89.0%; P < 0.001 across groups), and to enroll more participants
(median sample size, 306 participants; P < 0.001 across groups). Government-funded trials
were most likely to be placebo-controlled (56.2%), whereas trials funded by nonprofit or
nonfederal sources were least likely to be multicenter (24.6%) and tended to have the
smallest sample size (median, 50 participants). Industry-funded trials were also most
successful at enrolling the anticipated number of participants, with 84.9% of trials enrolling
at least 75% of the planned number of participants (P < 0.001 across groups). Only
government-funded trials included a substantial number of children, with 37.8% of trials
enrolling at least some pediatric patients (P < 0.001 across groups).
Trial Registration Practices
The funding source was also associated with characteristics of the ClinicalTrials.gov record
(Table 2). Government-funded trials were more likely to be appropriately registered before
the start date of the trial (25.7%), before study completion (75.3%), and before publication
of the study (95.1%) (P < 0.001 across groups for all 3 variables). However, government-
funded trials had the lowest proportion of reported primary outcomes (30.9%; P < 0.001
across groups). Provision of links to online abstracts of published results did not differ
across funding sources, but industry-sponsored trials were most likely to provide links to
unpublished results posted in study result registries or company Web sites. During the
period studied, very few trials had begun including actual study results in the record.
Effect of ICMJE Policy on Registration Practices
In September 2004, the ICMJE announced a new policy requiring trial registration before
patient enrollment for the trial to be eligible for publication in one of its member journals
(14). Specifically, trials initiated before 1 July 2005 needed to be registered before 13
September 2005, and any trials initiated on or after 1 July 2005 required preregistration.
Among ongoing trials as of 1 July 2005, 70.1% of industry-funded trials were compliant
with the ICMJE policy, compared with 80.5% of government-sponsored trials and 60.0% of
nonprofit or nonfederal organization–funded trials (P = 0.068 across groups). Of the 28 trials
in our study that were initiated after the start date of the policy, 50% were appropriately
preregistered, compared with 7.3% before this date (P < 0.001). Also, the number of trials
registered before study completion increased, with an overall increase from 22.0% among
trials completed before the policy began to 72.9% of trials completed after the policy took
effect (P < 0.001, Cochran–Mantel–Haenszel test controlling for primary funding source).
This improvement in timely registration occurred among trials in all funding categories,
increasing from 18.9% to 73.6% among industry-funded trials, 68.8% to 80.5% among
government-sponsored trials, and 1.9% to 67.1% among nonprofit or nonfederal source–
funded trials.
Characteristics of Trial Publications
Overall, 66.3% of trials had published results (Table 3). Industry-funded trials resulted in the
highest proportion of publications with favorable outcomes, with 85.4% of publications
positive for the test drug compared with 50.0% of publications among government-funded
trials and 71.9% of publications among nonprofit or nonfederal source–funded trials (P <
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0.001). Because 48% of the trials primarily funded by nonprofit or nonfederal organizations
also received some contributions from industry, this group was further categorized on the
basis of industry support. This revealed a difference in the reported trial outcomes: 85.0% of
trials funded by nonprofit or nonfederal sources with industry contributions reported
favorable outcomes, compared with 61.2% of those without industry support (P = 0.013).
Industry-funded trials were more likely to report positive findings across all trial phases, and
phase was not a significant determinant of the reported outcome (P = 0.70, Cochran–
Mantel–Haenszel test controlling for primary funding source) (Figure 3). In post hoc
multivariate analyses, factors associated with the reporting of a favorable outcome in
comparative trials included the primary funding source, whether the treatment indication
was approved by the FDA, and whether the study was conducted at a single center.
Trials funded by nonprofit or nonfederal organizations that did not receive industry
contributions were most likely (56.2%) and industry-funded trials least likely (32.4%) to be
published within 24 months of study completion (P < 0.005 across groups). Trials funded by
nonprofit or nonfederal organizations with industry contributions were also less likely than
those without industry funding to be published within 24 months (39.0%). The proportion of
trials published within 24 months of study completion increased between 2002 and 2006
after we controlled for primary funding source (increase from 9.5% to 54.4%; P < 0.001 for
trend). This increase was among trials in each of the funding categories (from 7.7% to
44.7% among industry-funded trials, 25.0% to 68.8% among government-funded trials, and
0% to 60.0% among nonprofit or nonfederal organization–funded trials).
Discussion
Trial characteristics, registration practices, and publication patterns were related to funding
source. Industry-funded trials were in more advanced phases of study and were most likely
to be multicenter trials using an active comparator study design. Trials funded by
government agencies had the highest rate of registration before the enrollment of
participants but were less than half as likely to include an a priori primary outcome in their
ClinicalTrials.gov study records. Industry-sponsored trials had the lowest rate of registration
even before trial publication and the lowest rate of publication within 24 months of study
completion.
Among the publications, those associated with trials primarily funded by industry were most
likely to report a positive outcome. Trials primarily funded by nonprofit or nonfederal
organizations that also received industry contributions were more likely than trials without
such support to report findings favoring the study drug.
These results are consistent with previous studies demonstrating an association between
industry funding and the reporting of results favoring experimental drugs marketed by the
sponsoring company (25–33). Systematic reviews of the literature have shown that industry-
funded trials are more than 4 times more likely to report findings supporting their product
than are trials without financial interests (34). A study of head-to-head drug comparisons of
statins manufactured by competing companies found that funding from the company
marketing the statin under study was associated with a 16-fold increase in the likelihood of
reporting results favoring the study drug (25). Other authors examining the source of this
association have identified biases in trial design and data analyses, biased interpretation and
reporting of results, and selective trial publication as possible causes (26, 32, 34–40).
We examined differences in trial characteristics based on funding source. Industry-funded
trials, for example, tended to be in phase 3 or 4. Later-phase trials may be more likely to
have positive outcomes because there is more certainty about the drug’s efficacy and safety
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at this advanced stage in the drug-development cycle. However, even after adjustment for
trial phase, we found a relationship between funding source and positive outcome.
Other factors may contribute to this association. For instance, the choice of study question to
be addressed in a trial is shaped by the intent of the investigation. Some trials are conducted
to substantiate the efficacy and safety of a drug, whereas others are conducted to explore
new indications. The study population selected may also affect the results, because it may
more or less closely resemble the postmarketing target population. Furthermore, selection of
the comparator treatment, drug doses, clinical end points, and duration of patient follow-up
may all affect study conclusions.
Unknown or incomplete information about trial details makes factors that influence trial
outcomes difficult to account for and measure (26, 32, 40). This limitation may be addressed
in the future by proposed changes to ClinicalTrials.gov, such as incorporating study
protocols and amendments into trial registrations and making FDA drug reviews public,
including their statistical analyses and comprehensive summaries of trial results by
independent experts (16, 33, 36, 38, 41, 42).
Although we could not assess all underlying factors, such as biases in trial design or data
interpretation, we found that a substantial number of trials were not registered before the
study start date or the publication of trial results. Without impartial, a priori registration of
trials, planned data analyses and study outcomes may be altered or omitted in favor of the
experimental treatment after trial data are available (33, 43, 44). The ICMJE’s requirement
of trial preregistration as a condition for publication eligibility, effective in September 2005,
has already resulted in a large increase in trial registration and will probably improve timely
registration in the future (45).
This study demonstrates several strengths and weaknesses of using ClinicalTrials.gov to
track factors leading to reporting of biased trial results. Trial start dates are easily assessed in
the registry records and allow appraisal of preregistration of trials, which is essential if the
registry is to be used to screen for outcome reporting bias (5, 38). Any changes made to the
record after initial submission are tracked, and earlier versions are archived and accessible in
the record (46). In our study sample, however, fewer than 10% of trials were registered
before the study start date. Concern remains that certain data, including descriptions of
primary outcomes, are insufficiently detailed, but the use of these trial records already
allows identification of inconsistencies between data elements reported in the registry and
those reported in the final article (5, 6).
Another benefit of the registry is that records indicate whether a trial is completed and
provide investigators with data fields to include references to resulting publications. Use of
unique clinical trial registry numbers in publications allows automated identification of trial
publications in MEDLINE and addition of references to the ClinicalTrials.gov record (46).
However, only about one third of published trials contained a link to a publication in the
record, and manual searches were required to determine whether the remaining trials had
been published. This finding is not surprising, considering that a recent study found that
37% of journals did not provide guidelines on registration requirements in instructions to
authors and 27% of published trials were not registered (5). To maximize the value of
clinical trial registries for monitoring and reducing publication bias, publication status must
be more consistently tracked in registration records and publications must contain
registration information.
A limitation of our study is that we could not confirm publication status for all trials. Some
trials may be incorrectly classified as unpublished, thus overestimating the degree of
publication bias. However, the search methods were rigorous, and publication status is
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unlikely to be misclassified in a systematic manner based on funding source. Another
limitation is that we allowed a minimum of 3 years between study completion and
publication, which may not have always been sufficient time for publication. Again, this is
unlikely to have affected our findings of the effect of funding sources on registration
practices or results reporting. Our approach to assessing whether trial findings were
favorable was systematic and consistent. However, publications were classified as reporting
favorable outcomes based on the statistical significance of results reported in the
publication; without further information on the quality of the trial design and conduct and
the analytic methods used, we cannot verify definitively whether the drug was truly effective
or safe. Also, many of the data fields in ClinicalTrials.gov have missing values.
We show a positive association between industry funding and reporting of favorable
outcomes among drug trials registered in ClinicalTrials.gov. Industry-sponsored trials were
also less likely to be published within 24 months of study completion. Investigators of trials
funded by either for-profit or nonprofit sources often did not comply with best practices
around trial registration and results publication, which may lead to a biased knowledge base.
For trial registries to maximize transparency around clinical trials and ensure the validity
and quality of the resulting scientific evidence, timely, accurate, and expanded information
entry and results disclosure are required.
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Context
ClinicalTrials.gov is a publicly available, Web-based registry that helps identify and
monitor clinical trials.
Contribution
This observational study of a sample of trials registered in ClinicalTrials.gov reports the
following funding sources for 546 selected drug trials: industry (63%), government
(14%), and nonprofit or nonfederal organizations (23%). Trials funded by industry more
often were phase 3 or 4 trials, used an active comparator, were multicenter, enrolled more
participants, were not published within 2 years of completion, and reported favorable
outcomes when published than did trials funded by other sources.
Caution
Detailed information on study conduct and quality were not assessed.
—The Editors
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Figure 1. Search and selection
* 5 trials in the final trial group studied both an antidepressant and an antipsychotic.
Bourgeois et al. Page 12
Ann Intern Med. Author manuscript; available in PMC 2012 June 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Percentage of trials, by funding source within drug classes
Industry was the primary funding source for all drug classes and funded more than two
thirds of trials among 4 of the classes. Five trials studied both an antidepressant and an
antipsychotic and are included in each class.
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Figure 3. Percentage of trials with reported favorable outcomes, by trial phase within funding
source
Trials funded by industry sources reported the highest percentage of favorable outcomes
across all trial phases. Trial phase was not a significant determinant of outcome (P = 0.70,
Cochran–Mantel–Haenszel test controlling for primary funding source). Phase 1 and 2 trials
were combined because of the small number of phase 1 trials (n = 13).
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Table 1
Characteristics of Drug Trials Registered in ClinicalTrials.gov
Characteristic Studies
(n = 546)
Primary Funding Source
Industry
(n = 346)
Government
(n = 74)
Nonprofit or
Nonfederal
(n = 126)
Indication FDA-approved, n (%)* 295 (54.0) 198 (57.2) 32 (43.2)   65 (51.6)
Study phase, n (%)†
    Phase 1, 2, or 2/3
    Phase 1, 2, or 2/3   88 (16.1)   35 (10.1) 26 (35.1)   27 (21.4)
    Phase 3 or 4 427 (78.2) 307 (88.7) 38 (51.4)   82 (65.1)
    Unknown
Study design: interventional vs. observational, n (%)
  31 (5.7)     4 (1.2) 10 (13.5)   17 (13.5)
  Interventional 540 (98.9) 342 (98.8) 73 (98.6) 125 (99.2)
    Comparator type in interventional trial (n = 540)‡
      Active agent comparator 180 (33.3) 126 (36.8) 17 (23.3)   37 (29.6)
      Placebo-controlled 235 (43.5) 132 (38.6) 41 (56.2)   62 (49.6)
      No comparator
    Randomization in trials with a comparator (n = 415)
125 (23.2)   84 (24.6) 15 (20.6)   26 (20.8)
      Yes 408 (98.3) 255 (98.8) 58 (100)   95 (96.0)
      No     6 (1.4)     3 (1.2)   0     3 (3.0)
      Unknown     1 (0.2)     0   0     1 (1.0)
    Blinding in trials with a comparator (n = 415)§
      Double-blind 337 (81.2) 212 (82.2) 50 (86.2)   75 (75.8)
      Single-blind     8 (1.9)     1 (0.4)   2 (3.5)     5 (5.1)
      No blinding   68 (16.4)   45 (17.4)   5 (8.6)   18 (18.2)
      Unknown     2 (0.5)     0   1 (1.7)     1 (1.0)
Multicenter trial, n (%)† 363 (66.5) 308 (89.0) 24 (32.4)   31 (24.6)
Median anticipated sample size (IQR), n†‖ 156 (60–432) 306 (126–566) 78 (40–150)   50 (24–85)
Final study sample ≥75% of anticipated, n (%)†¶
Age of study population, n (%)†
278 (79.0) 191 (84.9) 23 (59.0)   64 (72.7)
    Children only   30 (5.5)   19 (5.5)   1 (1.4)   10 (7.9)
    Children and adults   47 (8.6)   12 (3.5) 27 (36.5)   8 (6.4)
    Adults only 469 (85.9) 315 (91.0) 46 (62.2) 108 (85.7)
Length of study conduct, n (%)†
    <1 y 120 (22.0)   91 (26.3)   8 (10.8)   21 (16.7)
    1–2 y 158 (28.9) 113 (32.7) 15 (20.3)   30 (23.8)
    >2 y 209 (38.3)   88 (25.4) 50 (67.6)   71 (56.4)
    Unknown   59 (10.8)   54 (15.6)   1 (1.4)     4 (3.2)
FDA = U.S. Food and Drug Administration; IQR = interquartile range.
*
Five drugs (representing 11 trials) were not FDA-approved. The indication for which the drug is currently under FDA review was used in these
†P < 0.001 across variables for chi-square and Kruskal–Wallis tests for categorical and median values, respectively.
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‡P = 0.010 for active comparator vs. placebo-controlled trials.
§P = 0.02.
‖16 trials did not report sample size.
¶
Final sample size was available only for the 362 trials with publications.
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